PDCD1 and cancer: Consistently, Fan et al. developed an inhibitor, BEBT-908, which dual-targeted PI3K and HDAC, effectively inhibiting tumor cell growth and enhancing anti-PD1 therapy in mice by inducing immunogenic ferroptosis in cancer cells [67].